Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Medicine for Actionable Mutations at WFBCCC
NCT04111107Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in solid tumor, lymphoma and multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Primary endpoint: Progression Free Survival Ratio at 2 years. Started Apr 2020; status: terminated.
02
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04111107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111107.